FDA Denies Priority Review For GlaxoSmithKline’s HPV Vaccine Cervarix
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision could give Merck’s Gardasil an extra four months without HPV vaccine competition.
You may also be interested in...
GSK Receives “Complete Response” Letter For Cervarix BLA
Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.
GSK Receives “Complete Response” Letter For Cervarix BLA
Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.
GSK Rotarix Data Show Efficacy Against Virus Types Representing 98 Percent Of Rotavirus Disease
Data formed the basis of GSK’s BLA application for the rotavirus vaccine in the U.S., the company tells “The Pink Sheet” DAILY.